Document Detail


Early increase in autoantibodies against human oxidized low-density lipoprotein in hypertensive patients after blood pressure control.
MedLine Citation:
PMID:  19910928     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Oxidized lipoproteins and antioxidized low-density lipoprotein (anti-oxLDL) antibodies (Abs) have been detected in plasma in response to blood pressure (BP) elevation, suggesting the participation of the adaptive immune system. Therefore, treatment of hypertension may act on the immune response by decreasing oxidation stimuli. However, this issue has not been addressed. Thus, we have here analyzed anti-oxLDL Abs in untreated (naive) hypertensive patients shortly after initiation of antihypertensive therapeutic regimens.
METHODS: Titers of anti-oxLDL Abs were measured in subjects with recently diagnosed hypertension on stage 1 (n = 94), in primary prevention of coronary disease, with no other risk factors, and naive of antihypertensive medication at entry. Subjects were randomly assigned to receive perindopril, hydrochlorothiazide (HCTZ), or indapamide (INDA) for 12 weeks, with additional perindopril if necessary to achieve BP control. Abs against copper-oxidized LDL were measured by enzyme-linked immunosorbent assay.
RESULTS: Twelve-week antihypertensive treatment reduced both office-based and 24-h ambulatory BP measurements (P < 0.0005). The decrease in BP was accompanied by reduction in thiobarbituric acid-reactive substances (TBARS) (P < 0.05), increase in anti-oxLDL Ab titers (P < 0.005), and improvement in flow-mediated dilation (FMD) (P < 0.0005), independently of treatment. Although BP was reduced, we observed favorable changes in anti-oxLDL titers and FMD.
CONCLUSIONS: We observed that anti-oxLDL Ab titers increase after antihypertensive therapy in primary prevention when achieving BP targets. Our results are in agreement with the concept that propensity to oxidation is increased by essential hypertension and anti-oxLDL Abs may be protective and potential biomarkers for the follow-up of hypertension treatment.
Authors:
Sergio A Brandão; Maria C Izar; Simone M Fischer; Andreza O Santos; Carlos M Monteiro; Rui M Póvoa; Tatiana Helfenstein; Antonio C Carvalho; Andrea M Monteiro; Eduardo Ramos; Magnus Gidlund; Antonio M Figueiredo Neto; Francisco A Fonseca
Related Documents :
15117908 - Blood pressure control and physician management of hypertension in hospital hypertensio...
18326968 - Mechanisms and treatment of resistant hypertension.
10578218 - Improvement in treatment of hypertension has not reduced incidence of end-stage renal d...
8843528 - Ambulatory blood pressure on and off continuous positive airway pressure therapy for th...
6416748 - Radionuclide analysis of sequential changes in central circulatory volumes: inspiration...
23343138 - Blood pressure control and treatment adherence in hypertensive patients with metabolic ...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2009-11-12
Journal Detail:
Title:  American journal of hypertension     Volume:  23     ISSN:  1941-7225     ISO Abbreviation:  Am. J. Hypertens.     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-01-20     Completed Date:  2010-03-09     Revised Date:  2011-06-30    
Medline Journal Info:
Nlm Unique ID:  8803676     Medline TA:  Am J Hypertens     Country:  United States    
Other Details:
Languages:  eng     Pagination:  208-14     Citation Subset:  IM    
Affiliation:
Cardiology Division, Department of Medicine, Federal University of Sao Paulo, Sao Paulo, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antihypertensive Agents / therapeutic use*
Apolipoproteins / blood
Autoantibodies / metabolism*
Biological Markers
Blood Chemical Analysis
Blood Pressure / drug effects,  physiology*
Coronary Disease / blood,  complications
Endothelium, Vascular / physiology
Female
Humans
Hypertension / drug therapy*,  immunology*
Inflammation / blood
Lipids / blood
Lipoproteins, LDL / immunology*
Male
Middle Aged
Muscle Relaxation / physiology
Muscle, Smooth, Vascular / physiology
Vasodilation / physiology
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Apolipoproteins; 0/Autoantibodies; 0/Biological Markers; 0/Lipids; 0/Lipoproteins, LDL; 0/oxidized low density lipoprotein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  SCF(Dia2) regulates DNA replication forks during S-phase in budding yeast.
Next Document:  Effect of cocoa products on blood pressure: systematic review and meta-analysis.